ADAM9 Protein, Mouse, Recombinant (His)

一键复制产品信息

SPR兼容缓冲液

产品编号 TMPY-02404

ADAM9 Protein, Mouse, Recombinant (His) is expressed in HEK293 Cells. The accession number is Q61072.

ADAM9 Protein, Mouse, Recombinant (His)

一键复制产品信息

SPR兼容缓冲液

产品编号 TMPY-02404

ADAM9 Protein, Mouse, Recombinant (His) is expressed in HEK293 Cells. The accession number is Q61072.

规格	价格	库存
5 μg	¥ 582	6-8日内发货
10 μg	¥ 939	6-8日内发货
20 μg	¥ 1,590	5日内发货
50 μg	¥ 3,170	5日内发货
100 μg	¥ 5,200	5日内发货
200 μg	¥ 8,480	5日内发货
500 μg	¥ 18,800	5日内发货

大包装 & 定制

加入购物车

TargetMol 的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

实验操作小课堂

常见问题解答

资源下载

重组蛋白用户指南

产品信息

生物活性	Activity has not been tested. It is theoretically active, but we cannot guarantee it.
产品描述	ADAM9 Protein, Mouse, Recombinant (His) is expressed in HEK293 Cells. The accession number is Q61072.
种属	Mouse
表达系统	HEK293 Cells
标签	C-His
蛋白编号	Q61072
别名	Mltng,mKIAA0021,MDC9,AU020942,ADAM metallopeptidase domain 9
蛋白构建	Gly30-Asp697
蛋白纯度	> 90% as determined by Tris-Bis PAGE; > 90% as determined by HPLC
分子量	77.61 kDa (Predicted); 65-115 kDa (Reducing conditions due to glycosylation)
内毒素	< 1.0 EU/μg of the protein as determined by the LAL method.
蛋白性状	Solution
缓冲液	Supplied as 0.22μm filtered solution in PBS (pH 7.4).
复溶方法	A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.
存储	It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	Solutions are shipping with dry ice.
研究背景	A disintegrin and metalloproteinase 9 (ADAM9) is a member of the transmembrane ADAM family. It is expressed in different types of solid cancer and promotes tumor invasiveness. ADAM9 may be a prognostic marker for vestibular schwannomas (VS), and ADAM9 inhibition might have the potential as a systemic approach for the treatment of VS.